Skip to main content
Pharmena S.A. logo

Pharmena S.A. — Investor Relations & Filings

Ticker · PHR ISIN · PLPHRMN00011 LEI · 259400RHT936BBKW0955 WAR Manufacturing
Open in API
Filings indexed 649 across all filing types
Latest filing 2023-05-12 Board/Management Inform…
Country PL Poland
Listing WAR PHR

About Pharmena S.A.

https://www.pharmena.eu/

Pharmena S.A. is a specialty healthcare company focused on the development and commercialization of innovative products based on its patented active ingredient, 1-MNA. This molecule is a naturally occurring metabolite of niacin (vitamin B3) that plays a crucial role in cellular metabolism. The company's technology leverages the ability of 1-MNA to optimize the levels of the coenzyme NAD+, which decline with age and are vital for cellular function and regeneration. The product portfolio includes specialized cosmeceuticals, such as the Dermena line for hair loss, and dietary supplements designed to address the effects of cellular aging.

Recent filings

Filing Released Lang Actions
Powołanie Członków Zarządu na kolejną kadencję - Content (PL)
Board/Management Information Classification · 99% confidence The document text, written in Polish, announces the appointment of new members to the Management Board (Zarząd) of PHARMENA S.A. by the Supervisory Board (Rada Nadzorcza). It explicitly names the new President (Prezes Zarządu) and Vice-President (Wiceprezes Zarządu) and specifies the term length. This directly corresponds to the definition of 'Board/Management Information' (MANG), which covers announcements of changes in the company's board of directors or senior management.
2023-05-12 Polish
Przedłużenie istotnej umowy kredytowej z BGK - Content (PL)
Capital/Financing Update Classification · 98% confidence The document is a formal announcement in Polish by the management board ('Zarząd spółki') of Pharmena S.A. It details the amendment ('aneksowa') to an existing revolving credit agreement ('umowa o kredyt odnawialny') with Bank Gospodarstwa Krajowego (BGK), extending the term and listing the associated collateral (guarantees, liens on inventory, assignment of receivables). This action directly relates to the company's financing activities and capital structure management, specifically concerning debt and liquidity. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). It is not a general regulatory filing (RNS) because it is highly specific to financing, nor is it an earnings release or a report itself.
2023-04-24 Polish
Oświadczenie Rady Nadzorczej ws. audytora i komitetu audytu
Audit Report / Information Classification · 95% confidence The document is titled 'Raport 1 OŚWIADCZENIE RADY NADZORCZEJ PHARMENA S.A.' (Report 1 STATEMENT OF THE SUPERVISORY BOARD OF PHARMENA S.A.) and specifically addresses the selection of the auditing firm ('OŚWIADCZENIE DOTYCZĄCE POLITYKI WYBORU FIRMY AUDYTORSKIEJ'). It details compliance with regulations regarding the audit of annual financial statements and the functioning of the Audit Committee. This content directly relates to the formal audit process, accounting principles, and internal oversight structure, but it is a specific statement/report about the audit process rather than the full annual report (10-K) or a general audit opinion. Given the options, 'Audit Report / Information' (AR) is the most appropriate fit as it covers standalone audit reports and applied accounting principles/internal stress tests, which aligns with the supervisory board's statement regarding the auditor selection and compliance. FY 2022
2023-03-29 Polish
Oświadczenie Ocena Rady Nadzorczej za badania SF za 2022
Audit Report / Information Classification · 95% confidence The document is an 'Assessment of the Supervisory Board' (Ocena Rady Nadzorczej) regarding the company's annual financial statements and management report for the fiscal year 2022. It functions as an audit-related oversight document, confirming the board's review and positive evaluation of the financial reports prepared by the management and audited by an external auditor. It does not contain the full financial statements themselves, but rather the board's formal opinion on them. Therefore, it falls under the 'Audit Report / Information' category. FY 2022
2023-03-29 Polish
Informacja zarządu ws wyboru audytora za 2022 - podpis
Regulatory Filings Classification · 95% confidence The provided document text consists entirely of XML Digital Signature blocks (specifically XAdES signatures) used for verifying the authenticity and integrity of another document. The content references a file named "Pharmena_inform_zarzadu_ws_wyboru_audytora_2022.xhtml". The presence of signatures and the reference to an external document strongly suggest this is not the primary report itself, but rather metadata or a wrapper file. Since the content is purely technical validation data and does not contain financial narratives, results, or standard regulatory disclosures (like 10-K, ER, or IR), it falls best into the general regulatory/miscellaneous category, which is 'Regulatory Filings' (RNS), as it is a technical filing component rather than a specific financial report type. The document length is also relatively short for a full report.
2023-03-29 Polish
Informacja zarządu ws wyboru audytora za 2022
Audit Report / Information Classification · 99% confidence The document is titled 'INFORMACJA ZARZĄDU PHARMENA S.A. SPORZĄDZONA NA PODSTAWIE OŚWIADCZENIA RADY NADZORCZEJ W SPRAWIE PODMIOTU UPRAWNIONEGO DO BADANIA SPRAWOZDAŃ FINANSOWYCH' (Information of the Management Board of PHARMENA S.A. Prepared Based on the Supervisory Board's Statement Regarding the Entity Authorized to Audit Financial Statements). It explicitly discusses the selection of the auditing firm (PKF Consult Sp. z o.o. Sp. k.) for the 2022 annual financial statements and confirms compliance with auditing regulations, rotation rules, and internal policies regarding the auditor. This content directly relates to the formal audit process and the resulting report's integrity, fitting the definition of an Audit Report / Information (AR), which covers applied accounting principles and results of internal/regulatory stress tests, or in this case, the foundational information supporting the audit. FY 2022
2023-03-29 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.